



February 14, 2024

Lion Corporation

**Notice Concerning the Transfer of Health Tonic Drink Brands and  
One Topical Anti-Inflammatory Analgesic Brand**

Lion Corporation (Representative Director, President and Executive Officer: Masayuki Takemori) decided to transfer the *Guronsan* and *Gromonto* brands of health tonic drinks to LEC, Inc. (hereinafter, LEC) and the *Halix* brand of topical anti-inflammatory analgesics to Teikoku Seiyaku Co., Ltd. (hereinafter, Teikoku Seiyaku), as of today concluding business transfer agreements with each company.

**1. Purpose of the Transfer**

In line with the Lion Group's medium-term management plan for 2022–2024, Vision2030 1st STAGE, Lion has been aiming to implement growth strategies and transforming its management base to become even more resilient to environmental changes. Accordingly, the Company decided to conduct this transfer as part of its efforts to revise its business portfolio.

**2. *Guronsan* and *Guromont***

**(1) Overview of Transferee**

|                                  |   |
|----------------------------------|---|
| Name                             | LEC, Inc.   |
| Name and title of representative | Mitsuo Aoki, Chairman and Representative Director               |
| Location                         | 8F Kyobashi Trust Tower, 2-1-3, Kyobashi, Chuo-ku, Tokyo, Japan |
| Date of establishment            | March 17, 1983  |
| Business content                 | Manufacture and sale of household goods, etc.                   |
| Capital                          | 5,491 million yen   |
| Listing                          | Listed (Prime Market of Tokyo Stock Exchange: 7874)             |

## (2) Products to be Transferred

*Guronsan Oral Liquid, Guronsan Strong Oral Liquid, New Guromont A*



*Guronsan Oral Liquid*  
(Class 3 OTC drug)



*Guronsan Strong Oral Liquid*  
(Class 3 OTC drug)



*New Guromont A*  
(Designated quasi-drug)

## (3) Transfer Date

June 28, 2024 (Planned)

## 3. Halix

### (1) Overview of Transferee

|                                  |  |
|----------------------------------|--|
| Name                             | Teikoku Seiyaku Co., Ltd.                          |
| Name add title of representative | Misako Fujioka, President & CEO                    |
| Location                         | 567 Sanbonmatsu, Higashikagawa, Kagawa, Japan      |
| Date of establishment            | May 23, 1918                                       |
| Business content                 | Manufacture and sale of pharmaceutical goods, etc. |
| Capital                          | 100 million yen                                    |
| Listing                          | Unlisted   |

## (2) Products to be Transferred

*Halix 55 EX Cool A, Halix 55 EX Warm A, Halix 55 ID Plus*



*Halix 55 EX Cool A*  
(Class 3 OTC drug)



*Halix 55 EX Warm A*  
(Class 3 OTC drug)



*Halix 55 ID Plus*  
(Class 2 OTC drug)

## (3) Transfer Date

March 29, 2024 (Planned)